nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—myometrium—uterine cancer	0.0433	0.114	CbGeAlD
Plerixafor—CXCR4—epithelium—uterine cancer	0.034	0.0891	CbGeAlD
Plerixafor—CXCR4—uterine cervix—uterine cancer	0.0337	0.0884	CbGeAlD
Plerixafor—CXCR4—smooth muscle tissue—uterine cancer	0.0328	0.0859	CbGeAlD
Plerixafor—CXCR4—Early Phase of HIV Life Cycle—HMGA1—uterine cancer	0.0325	0.212	CbGpPWpGaD
Plerixafor—CXCR4—decidua—uterine cancer	0.0321	0.0842	CbGeAlD
Plerixafor—CXCR4—renal system—uterine cancer	0.0315	0.0827	CbGeAlD
Plerixafor—CXCR4—endometrium—uterine cancer	0.0305	0.0799	CbGeAlD
Plerixafor—CXCR4—mammalian vulva—uterine cancer	0.0295	0.0773	CbGeAlD
Plerixafor—CXCR4—uterus—uterine cancer	0.0281	0.0737	CbGeAlD
Plerixafor—CXCR4—female reproductive system—uterine cancer	0.0253	0.0662	CbGeAlD
Plerixafor—CXCR4—female gonad—uterine cancer	0.023	0.0603	CbGeAlD
Plerixafor—CXCR4—vagina—uterine cancer	0.0228	0.0599	CbGeAlD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—CSF3—uterine cancer	0.022	0.144	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—INHBA—uterine cancer	0.0166	0.108	CbGpPWpGaD
Plerixafor—CXCR4—lymph node—uterine cancer	0.0148	0.0387	CbGeAlD
Plerixafor—Induration—Etoposide—uterine cancer	0.0096	0.0206	CcSEcCtD
Plerixafor—Musculoskeletal pain—Progesterone—uterine cancer	0.0085	0.0182	CcSEcCtD
Plerixafor—Musculoskeletal pain—Medroxyprogesterone Acetate—uterine cancer	0.0077	0.0165	CcSEcCtD
Plerixafor—Injection site reaction—Medroxyprogesterone Acetate—uterine cancer	0.00756	0.0162	CcSEcCtD
Plerixafor—Swelling—Progesterone—uterine cancer	0.00691	0.0148	CcSEcCtD
Plerixafor—Swelling—Medroxyprogesterone Acetate—uterine cancer	0.00626	0.0134	CcSEcCtD
Plerixafor—CXCR4—S1P3 pathway—VEGFA—uterine cancer	0.00617	0.0403	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	0.00615	0.0402	CbGpPWpGaD
Plerixafor—Abdominal distension—Progesterone—uterine cancer	0.0053	0.0114	CcSEcCtD
Plerixafor—CXCR4—HIV Life Cycle—HMGA1—uterine cancer	0.00527	0.0344	CbGpPWpGaD
Plerixafor—Abdominal discomfort—Progesterone—uterine cancer	0.00505	0.0108	CcSEcCtD
Plerixafor—Orthostatic hypotension—Medroxyprogesterone Acetate—uterine cancer	0.00504	0.0108	CcSEcCtD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CCL2—uterine cancer	0.00504	0.0329	CbGpPWpGaD
Plerixafor—Pain—Carboplatin—uterine cancer	0.00488	0.0105	CcSEcCtD
Plerixafor—Abdominal distension—Medroxyprogesterone Acetate—uterine cancer	0.0048	0.0103	CcSEcCtD
Plerixafor—Abdominal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00458	0.00983	CcSEcCtD
Plerixafor—Inflammation—Etoposide—uterine cancer	0.00443	0.00951	CcSEcCtD
Plerixafor—Haemoglobin—Progesterone—uterine cancer	0.00424	0.0091	CcSEcCtD
Plerixafor—Haemorrhage—Progesterone—uterine cancer	0.00422	0.00905	CcSEcCtD
Plerixafor—Connective tissue disorder—Progesterone—uterine cancer	0.00414	0.0089	CcSEcCtD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CXCL8—uterine cancer	0.00399	0.026	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—AKT1—uterine cancer	0.00394	0.0257	CbGpPWpGaD
Plerixafor—Haemoglobin—Medroxyprogesterone Acetate—uterine cancer	0.00384	0.00825	CcSEcCtD
Plerixafor—Haemorrhage—Medroxyprogesterone Acetate—uterine cancer	0.00382	0.0082	CcSEcCtD
Plerixafor—Immune system disorder—Progesterone—uterine cancer	0.00381	0.00818	CcSEcCtD
Plerixafor—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	0.00375	0.00806	CcSEcCtD
Plerixafor—Mental disorder—Progesterone—uterine cancer	0.00369	0.00793	CcSEcCtD
Plerixafor—Erythema—Progesterone—uterine cancer	0.00367	0.00788	CcSEcCtD
Plerixafor—CXCR4—HIV Infection—HMGA1—uterine cancer	0.00364	0.0238	CbGpPWpGaD
Plerixafor—Flatulence—Progesterone—uterine cancer	0.00362	0.00777	CcSEcCtD
Plerixafor—Swelling—Etoposide—uterine cancer	0.00353	0.00759	CcSEcCtD
Plerixafor—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00345	0.00741	CcSEcCtD
Plerixafor—Ill-defined disorder—Progesterone—uterine cancer	0.00341	0.00731	CcSEcCtD
Plerixafor—Mental disorder—Medroxyprogesterone Acetate—uterine cancer	0.00335	0.00719	CcSEcCtD
Plerixafor—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.00333	0.00714	CcSEcCtD
Plerixafor—Malaise—Progesterone—uterine cancer	0.00331	0.00711	CcSEcCtD
Plerixafor—Syncope—Progesterone—uterine cancer	0.00329	0.00707	CcSEcCtD
Plerixafor—Flatulence—Medroxyprogesterone Acetate—uterine cancer	0.00328	0.00704	CcSEcCtD
Plerixafor—Loss of consciousness—Progesterone—uterine cancer	0.00323	0.00693	CcSEcCtD
Plerixafor—Arthralgia—Progesterone—uterine cancer	0.00312	0.00671	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.0031	0.00666	CcSEcCtD
Plerixafor—Discomfort—Progesterone—uterine cancer	0.00309	0.00663	CcSEcCtD
Plerixafor—Ill-defined disorder—Medroxyprogesterone Acetate—uterine cancer	0.00309	0.00663	CcSEcCtD
Plerixafor—Dry mouth—Progesterone—uterine cancer	0.00306	0.00656	CcSEcCtD
Plerixafor—Malaise—Medroxyprogesterone Acetate—uterine cancer	0.003	0.00644	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—EP300—uterine cancer	0.003	0.0196	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Progesterone—uterine cancer	0.003	0.00643	CcSEcCtD
Plerixafor—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.00298	0.00641	CcSEcCtD
Plerixafor—Shock—Progesterone—uterine cancer	0.00295	0.00633	CcSEcCtD
Plerixafor—Nervous system disorder—Progesterone—uterine cancer	0.00294	0.00631	CcSEcCtD
Plerixafor—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.00292	0.00628	CcSEcCtD
Plerixafor—Skin disorder—Progesterone—uterine cancer	0.00291	0.00625	CcSEcCtD
Plerixafor—Hyperhidrosis—Progesterone—uterine cancer	0.0029	0.00622	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	0.00284	0.0185	CbGpPWpGaD
Plerixafor—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.00283	0.00608	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00281	0.00604	CcSEcCtD
Plerixafor—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.0028	0.00601	CcSEcCtD
Plerixafor—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00277	0.00595	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Progesterone—uterine cancer	0.00273	0.00586	CcSEcCtD
Plerixafor—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00271	0.00583	CcSEcCtD
Plerixafor—Insomnia—Progesterone—uterine cancer	0.00271	0.00582	CcSEcCtD
Plerixafor—Paraesthesia—Progesterone—uterine cancer	0.00269	0.00578	CcSEcCtD
Plerixafor—Dyspnoea—Progesterone—uterine cancer	0.00267	0.00574	CcSEcCtD
Plerixafor—Shock—Medroxyprogesterone Acetate—uterine cancer	0.00267	0.00574	CcSEcCtD
Plerixafor—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00266	0.00572	CcSEcCtD
Plerixafor—Dyspepsia—Progesterone—uterine cancer	0.00264	0.00566	CcSEcCtD
Plerixafor—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00264	0.00566	CcSEcCtD
Plerixafor—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.00262	0.00564	CcSEcCtD
Plerixafor—Erythema—Dactinomycin—uterine cancer	0.00259	0.00557	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Progesterone—uterine cancer	0.00259	0.00555	CcSEcCtD
Plerixafor—Fatigue—Progesterone—uterine cancer	0.00258	0.00555	CcSEcCtD
Plerixafor—Constipation—Progesterone—uterine cancer	0.00256	0.0055	CcSEcCtD
Plerixafor—Pain—Progesterone—uterine cancer	0.00256	0.0055	CcSEcCtD
Plerixafor—Inflammation—Epirubicin—uterine cancer	0.00248	0.00533	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00247	0.00531	CcSEcCtD
Plerixafor—Feeling abnormal—Progesterone—uterine cancer	0.00247	0.0053	CcSEcCtD
Plerixafor—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00245	0.00527	CcSEcCtD
Plerixafor—Gastrointestinal pain—Progesterone—uterine cancer	0.00245	0.00526	CcSEcCtD
Plerixafor—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.00244	0.00523	CcSEcCtD
Plerixafor—Musculoskeletal pain—Epirubicin—uterine cancer	0.00244	0.00523	CcSEcCtD
Plerixafor—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00242	0.0052	CcSEcCtD
Plerixafor—Ill-defined disorder—Dactinomycin—uterine cancer	0.00241	0.00517	CcSEcCtD
Plerixafor—Injection site reaction—Epirubicin—uterine cancer	0.00239	0.00514	CcSEcCtD
Plerixafor—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00239	0.00513	CcSEcCtD
Plerixafor—Urticaria—Progesterone—uterine cancer	0.00238	0.00511	CcSEcCtD
Plerixafor—Abdominal pain—Progesterone—uterine cancer	0.00237	0.00509	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00234	0.00503	CcSEcCtD
Plerixafor—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00234	0.00503	CcSEcCtD
Plerixafor—Malaise—Dactinomycin—uterine cancer	0.00234	0.00502	CcSEcCtD
Plerixafor—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00232	0.00498	CcSEcCtD
Plerixafor—Inflammation—Doxorubicin—uterine cancer	0.0023	0.00493	CcSEcCtD
Plerixafor—Musculoskeletal pain—Doxorubicin—uterine cancer	0.00225	0.00484	CcSEcCtD
Plerixafor—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00224	0.0048	CcSEcCtD
Plerixafor—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00222	0.00477	CcSEcCtD
Plerixafor—Injection site reaction—Doxorubicin—uterine cancer	0.00221	0.00476	CcSEcCtD
Plerixafor—Hypersensitivity—Progesterone—uterine cancer	0.00221	0.00474	CcSEcCtD
Plerixafor—Discomfort—Dactinomycin—uterine cancer	0.00218	0.00469	CcSEcCtD
Plerixafor—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00216	0.00463	CcSEcCtD
Plerixafor—Asthenia—Progesterone—uterine cancer	0.00215	0.00462	CcSEcCtD
Plerixafor—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00215	0.00461	CcSEcCtD
Plerixafor—Pruritus—Progesterone—uterine cancer	0.00212	0.00455	CcSEcCtD
Plerixafor—Diarrhoea—Progesterone—uterine cancer	0.00205	0.0044	CcSEcCtD
Plerixafor—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.002	0.00429	CcSEcCtD
Plerixafor—Dizziness—Progesterone—uterine cancer	0.00198	0.00425	CcSEcCtD
Plerixafor—Immune system disorder—Etoposide—uterine cancer	0.00195	0.00418	CcSEcCtD
Plerixafor—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00195	0.00418	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00193	0.00414	CcSEcCtD
Plerixafor—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00192	0.00412	CcSEcCtD
Plerixafor—Vomiting—Progesterone—uterine cancer	0.0019	0.00409	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCL2—uterine cancer	0.0019	0.0124	CbGpPWpGaD
Plerixafor—Rash—Progesterone—uterine cancer	0.00189	0.00406	CcSEcCtD
Plerixafor—Dermatitis—Progesterone—uterine cancer	0.00189	0.00405	CcSEcCtD
Plerixafor—Headache—Progesterone—uterine cancer	0.00188	0.00403	CcSEcCtD
Plerixafor—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00186	0.00399	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CA—uterine cancer	0.00183	0.0119	CbGpPWpGaD
Plerixafor—Fatigue—Dactinomycin—uterine cancer	0.00183	0.00392	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—AKT1—uterine cancer	0.00181	0.0118	CbGpPWpGaD
Plerixafor—Pain—Dactinomycin—uterine cancer	0.00181	0.00389	CcSEcCtD
Plerixafor—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00179	0.00385	CcSEcCtD
Plerixafor—Nausea—Progesterone—uterine cancer	0.00178	0.00382	CcSEcCtD
Plerixafor—Feeling abnormal—Dactinomycin—uterine cancer	0.00174	0.00375	CcSEcCtD
Plerixafor—CXCR4—Disease—AKR1B10—uterine cancer	0.00174	0.0114	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Etoposide—uterine cancer	0.00174	0.00374	CcSEcCtD
Plerixafor—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00173	0.00372	CcSEcCtD
Plerixafor—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00173	0.00371	CcSEcCtD
Plerixafor—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00171	0.00368	CcSEcCtD
Plerixafor—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00171	0.00367	CcSEcCtD
Plerixafor—Headache—Medroxyprogesterone Acetate—uterine cancer	0.0017	0.00365	CcSEcCtD
Plerixafor—Malaise—Etoposide—uterine cancer	0.00169	0.00364	CcSEcCtD
Plerixafor—Abdominal pain—Dactinomycin—uterine cancer	0.00167	0.00359	CcSEcCtD
Plerixafor—Loss of consciousness—Etoposide—uterine cancer	0.00165	0.00354	CcSEcCtD
Plerixafor—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00161	0.00346	CcSEcCtD
Plerixafor—Orthostatic hypotension—Epirubicin—uterine cancer	0.0016	0.00343	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.00159	0.00341	CcSEcCtD
Plerixafor—Discomfort—Etoposide—uterine cancer	0.00158	0.00339	CcSEcCtD
Plerixafor—Hypersensitivity—Dactinomycin—uterine cancer	0.00156	0.00335	CcSEcCtD
Plerixafor—Anaphylactic shock—Etoposide—uterine cancer	0.00153	0.00329	CcSEcCtD
Plerixafor—Abdominal distension—Epirubicin—uterine cancer	0.00152	0.00327	CcSEcCtD
Plerixafor—Asthenia—Dactinomycin—uterine cancer	0.00152	0.00326	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CXCL8—uterine cancer	0.0015	0.00979	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—AKT1—uterine cancer	0.00149	0.00975	CbGpPWpGaD
Plerixafor—Skin disorder—Etoposide—uterine cancer	0.00149	0.0032	CcSEcCtD
Plerixafor—Hyperhidrosis—Etoposide—uterine cancer	0.00148	0.00318	CcSEcCtD
Plerixafor—Orthostatic hypotension—Doxorubicin—uterine cancer	0.00148	0.00317	CcSEcCtD
Plerixafor—Diarrhoea—Dactinomycin—uterine cancer	0.00145	0.00311	CcSEcCtD
Plerixafor—CXCR4—Disease—RNF43—uterine cancer	0.00144	0.00943	CbGpPWpGaD
Plerixafor—Abdominal distension—Doxorubicin—uterine cancer	0.00141	0.00302	CcSEcCtD
Plerixafor—Paraesthesia—Etoposide—uterine cancer	0.00138	0.00295	CcSEcCtD
Plerixafor—Dyspnoea—Etoposide—uterine cancer	0.00137	0.00293	CcSEcCtD
Plerixafor—Vomiting—Dactinomycin—uterine cancer	0.00135	0.00289	CcSEcCtD
Plerixafor—Rash—Dactinomycin—uterine cancer	0.00133	0.00287	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Etoposide—uterine cancer	0.00132	0.00284	CcSEcCtD
Plerixafor—Fatigue—Etoposide—uterine cancer	0.00132	0.00284	CcSEcCtD
Plerixafor—Constipation—Etoposide—uterine cancer	0.00131	0.00281	CcSEcCtD
Plerixafor—Pain—Etoposide—uterine cancer	0.00131	0.00281	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.00127	0.00831	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—CXCL8—uterine cancer	0.00127	0.00826	CbGpPWpGaD
Plerixafor—Feeling abnormal—Etoposide—uterine cancer	0.00126	0.00271	CcSEcCtD
Plerixafor—Nausea—Dactinomycin—uterine cancer	0.00126	0.0027	CcSEcCtD
Plerixafor—Gastrointestinal pain—Etoposide—uterine cancer	0.00125	0.00269	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—AKR1B10—uterine cancer	0.00122	0.00797	CbGpPWpGaD
Plerixafor—Urticaria—Etoposide—uterine cancer	0.00122	0.00261	CcSEcCtD
Plerixafor—Haemoglobin—Epirubicin—uterine cancer	0.00122	0.00261	CcSEcCtD
Plerixafor—Abdominal pain—Etoposide—uterine cancer	0.00121	0.0026	CcSEcCtD
Plerixafor—Haemorrhage—Epirubicin—uterine cancer	0.00121	0.0026	CcSEcCtD
Plerixafor—CXCR4—Disease—AKR1C1—uterine cancer	0.00119	0.00777	CbGpPWpGaD
Plerixafor—Connective tissue disorder—Epirubicin—uterine cancer	0.00119	0.00255	CcSEcCtD
Plerixafor—Hypersensitivity—Etoposide—uterine cancer	0.00113	0.00242	CcSEcCtD
Plerixafor—Haemoglobin—Doxorubicin—uterine cancer	0.00112	0.00241	CcSEcCtD
Plerixafor—Haemorrhage—Doxorubicin—uterine cancer	0.00112	0.0024	CcSEcCtD
Plerixafor—Asthenia—Etoposide—uterine cancer	0.0011	0.00236	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—uterine cancer	0.0011	0.00236	CcSEcCtD
Plerixafor—Immune system disorder—Epirubicin—uterine cancer	0.00109	0.00235	CcSEcCtD
Plerixafor—Pruritus—Etoposide—uterine cancer	0.00108	0.00233	CcSEcCtD
Plerixafor—Mental disorder—Epirubicin—uterine cancer	0.00106	0.00227	CcSEcCtD
Plerixafor—Erythema—Epirubicin—uterine cancer	0.00105	0.00226	CcSEcCtD
Plerixafor—Diarrhoea—Etoposide—uterine cancer	0.00105	0.00225	CcSEcCtD
Plerixafor—Flatulence—Epirubicin—uterine cancer	0.00104	0.00223	CcSEcCtD
Plerixafor—CXCR4—Disease—DCN—uterine cancer	0.00103	0.00672	CbGpPWpGaD
Plerixafor—Dizziness—Etoposide—uterine cancer	0.00101	0.00218	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RNF43—uterine cancer	0.00101	0.00661	CbGpPWpGaD
Plerixafor—Immune system disorder—Doxorubicin—uterine cancer	0.00101	0.00217	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.00101	0.00657	CbGpPWpGaD
Plerixafor—Mental disorder—Doxorubicin—uterine cancer	0.00098	0.0021	CcSEcCtD
Plerixafor—Ill-defined disorder—Epirubicin—uterine cancer	0.000976	0.0021	CcSEcCtD
Plerixafor—Vomiting—Etoposide—uterine cancer	0.000974	0.00209	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—uterine cancer	0.000974	0.00209	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CCL2—uterine cancer	0.000969	0.00633	CbGpPWpGaD
Plerixafor—Rash—Etoposide—uterine cancer	0.000966	0.00207	CcSEcCtD
Plerixafor—Dermatitis—Etoposide—uterine cancer	0.000965	0.00207	CcSEcCtD
Plerixafor—Headache—Etoposide—uterine cancer	0.00096	0.00206	CcSEcCtD
Plerixafor—Flatulence—Doxorubicin—uterine cancer	0.00096	0.00206	CcSEcCtD
Plerixafor—Malaise—Epirubicin—uterine cancer	0.000949	0.00204	CcSEcCtD
Plerixafor—Syncope—Epirubicin—uterine cancer	0.000944	0.00203	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—INHBA—uterine cancer	0.000925	0.00604	CbGpPWpGaD
Plerixafor—Loss of consciousness—Epirubicin—uterine cancer	0.000925	0.00199	CcSEcCtD
Plerixafor—CXCR4—Disease—AKR1C3—uterine cancer	0.000916	0.00598	CbGpPWpGaD
Plerixafor—Nausea—Etoposide—uterine cancer	0.00091	0.00195	CcSEcCtD
Plerixafor—Ill-defined disorder—Doxorubicin—uterine cancer	0.000903	0.00194	CcSEcCtD
Plerixafor—Arthralgia—Epirubicin—uterine cancer	0.000896	0.00192	CcSEcCtD
Plerixafor—CXCR4—Disease—HMGA1—uterine cancer	0.000892	0.00583	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.00089	0.00191	CcSEcCtD
Plerixafor—Discomfort—Epirubicin—uterine cancer	0.000885	0.0019	CcSEcCtD
Plerixafor—Malaise—Doxorubicin—uterine cancer	0.000878	0.00189	CcSEcCtD
Plerixafor—Dry mouth—Epirubicin—uterine cancer	0.000876	0.00188	CcSEcCtD
Plerixafor—Syncope—Doxorubicin—uterine cancer	0.000873	0.00188	CcSEcCtD
Plerixafor—Anaphylactic shock—Epirubicin—uterine cancer	0.000859	0.00184	CcSEcCtD
Plerixafor—Loss of consciousness—Doxorubicin—uterine cancer	0.000856	0.00184	CcSEcCtD
Plerixafor—Shock—Epirubicin—uterine cancer	0.000845	0.00181	CcSEcCtD
Plerixafor—Nervous system disorder—Epirubicin—uterine cancer	0.000842	0.00181	CcSEcCtD
Plerixafor—Skin disorder—Epirubicin—uterine cancer	0.000834	0.00179	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—AKR1C1—uterine cancer	0.000833	0.00544	CbGpPWpGaD
Plerixafor—Hyperhidrosis—Epirubicin—uterine cancer	0.00083	0.00178	CcSEcCtD
Plerixafor—Arthralgia—Doxorubicin—uterine cancer	0.000829	0.00178	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000823	0.00177	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—uterine cancer	0.000819	0.00176	CcSEcCtD
Plerixafor—CXCR4—Disease—FBXW7—uterine cancer	0.000816	0.00533	CbGpPWpGaD
Plerixafor—Dry mouth—Doxorubicin—uterine cancer	0.000811	0.00174	CcSEcCtD
Plerixafor—Anaphylactic shock—Doxorubicin—uterine cancer	0.000795	0.00171	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000783	0.00168	CcSEcCtD
Plerixafor—Shock—Doxorubicin—uterine cancer	0.000782	0.00168	CcSEcCtD
Plerixafor—Nervous system disorder—Doxorubicin—uterine cancer	0.000779	0.00167	CcSEcCtD
Plerixafor—Insomnia—Epirubicin—uterine cancer	0.000777	0.00167	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—uterine cancer	0.000772	0.00166	CcSEcCtD
Plerixafor—Paraesthesia—Epirubicin—uterine cancer	0.000771	0.00166	CcSEcCtD
Plerixafor—Hyperhidrosis—Doxorubicin—uterine cancer	0.000768	0.00165	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CXCL8—uterine cancer	0.000766	0.005	CbGpPWpGaD
Plerixafor—Dyspnoea—Epirubicin—uterine cancer	0.000766	0.00164	CcSEcCtD
Plerixafor—Dyspepsia—Epirubicin—uterine cancer	0.000756	0.00162	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000741	0.00159	CcSEcCtD
Plerixafor—Fatigue—Epirubicin—uterine cancer	0.00074	0.00159	CcSEcCtD
Plerixafor—Pain—Epirubicin—uterine cancer	0.000734	0.00158	CcSEcCtD
Plerixafor—Constipation—Epirubicin—uterine cancer	0.000734	0.00158	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000724	0.00156	CcSEcCtD
Plerixafor—Insomnia—Doxorubicin—uterine cancer	0.000719	0.00154	CcSEcCtD
Plerixafor—Paraesthesia—Doxorubicin—uterine cancer	0.000714	0.00153	CcSEcCtD
Plerixafor—Dyspnoea—Doxorubicin—uterine cancer	0.000709	0.00152	CcSEcCtD
Plerixafor—Feeling abnormal—Epirubicin—uterine cancer	0.000708	0.00152	CcSEcCtD
Plerixafor—Gastrointestinal pain—Epirubicin—uterine cancer	0.000702	0.00151	CcSEcCtD
Plerixafor—Dyspepsia—Doxorubicin—uterine cancer	0.0007	0.0015	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000686	0.00147	CcSEcCtD
Plerixafor—Fatigue—Doxorubicin—uterine cancer	0.000685	0.00147	CcSEcCtD
Plerixafor—Urticaria—Epirubicin—uterine cancer	0.000682	0.00147	CcSEcCtD
Plerixafor—Pain—Doxorubicin—uterine cancer	0.00068	0.00146	CcSEcCtD
Plerixafor—Constipation—Doxorubicin—uterine cancer	0.00068	0.00146	CcSEcCtD
Plerixafor—Abdominal pain—Epirubicin—uterine cancer	0.000679	0.00146	CcSEcCtD
Plerixafor—Feeling abnormal—Doxorubicin—uterine cancer	0.000655	0.00141	CcSEcCtD
Plerixafor—Gastrointestinal pain—Doxorubicin—uterine cancer	0.00065	0.0014	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—AKR1C3—uterine cancer	0.000641	0.00419	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN2B—uterine cancer	0.000639	0.00418	CbGpPWpGaD
Plerixafor—Hypersensitivity—Epirubicin—uterine cancer	0.000633	0.00136	CcSEcCtD
Plerixafor—Urticaria—Doxorubicin—uterine cancer	0.000631	0.00136	CcSEcCtD
Plerixafor—Abdominal pain—Doxorubicin—uterine cancer	0.000628	0.00135	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PGR—uterine cancer	0.000625	0.00408	CbGpPWpGaD
Plerixafor—Asthenia—Epirubicin—uterine cancer	0.000616	0.00132	CcSEcCtD
Plerixafor—Pruritus—Epirubicin—uterine cancer	0.000608	0.00131	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—YWHAE—uterine cancer	0.000596	0.00389	CbGpPWpGaD
Plerixafor—Diarrhoea—Epirubicin—uterine cancer	0.000588	0.00126	CcSEcCtD
Plerixafor—Hypersensitivity—Doxorubicin—uterine cancer	0.000586	0.00126	CcSEcCtD
Plerixafor—CXCR4—Disease—SMAD3—uterine cancer	0.000584	0.00381	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FBXW7—uterine cancer	0.000571	0.00373	CbGpPWpGaD
Plerixafor—Asthenia—Doxorubicin—uterine cancer	0.00057	0.00122	CcSEcCtD
Plerixafor—Dizziness—Epirubicin—uterine cancer	0.000568	0.00122	CcSEcCtD
Plerixafor—Pruritus—Doxorubicin—uterine cancer	0.000562	0.00121	CcSEcCtD
Plerixafor—CXCR4—Disease—FGFR2—uterine cancer	0.000557	0.00364	CbGpPWpGaD
Plerixafor—Vomiting—Epirubicin—uterine cancer	0.000546	0.00117	CcSEcCtD
Plerixafor—Diarrhoea—Doxorubicin—uterine cancer	0.000544	0.00117	CcSEcCtD
Plerixafor—Rash—Epirubicin—uterine cancer	0.000542	0.00116	CcSEcCtD
Plerixafor—Dermatitis—Epirubicin—uterine cancer	0.000541	0.00116	CcSEcCtD
Plerixafor—Headache—Epirubicin—uterine cancer	0.000538	0.00116	CcSEcCtD
Plerixafor—CXCR4—Disease—MTHFR—uterine cancer	0.000536	0.0035	CbGpPWpGaD
Plerixafor—Dizziness—Doxorubicin—uterine cancer	0.000526	0.00113	CcSEcCtD
Plerixafor—Nausea—Epirubicin—uterine cancer	0.00051	0.0011	CcSEcCtD
Plerixafor—Vomiting—Doxorubicin—uterine cancer	0.000505	0.00109	CcSEcCtD
Plerixafor—Rash—Doxorubicin—uterine cancer	0.000501	0.00108	CcSEcCtD
Plerixafor—Dermatitis—Doxorubicin—uterine cancer	0.000501	0.00108	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—STK11—uterine cancer	0.000499	0.00326	CbGpPWpGaD
Plerixafor—Headache—Doxorubicin—uterine cancer	0.000498	0.00107	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CCL2—uterine cancer	0.000497	0.00325	CbGpPWpGaD
Plerixafor—Nausea—Doxorubicin—uterine cancer	0.000472	0.00101	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SOCS3—uterine cancer	0.000468	0.00305	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN2B—uterine cancer	0.000448	0.00292	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF1R—uterine cancer	0.000435	0.00284	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL8—uterine cancer	0.000433	0.00283	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SMAD3—uterine cancer	0.000409	0.00267	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CXCL8—uterine cancer	0.000393	0.00257	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGFR2—uterine cancer	0.00039	0.00255	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB2—uterine cancer	0.00035	0.00228	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ESR1—uterine cancer	0.000334	0.00218	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1B—uterine cancer	0.000324	0.00212	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—NRAS—uterine cancer	0.000315	0.00206	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CTNNB1—uterine cancer	0.000306	0.002	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTEN—uterine cancer	0.000298	0.00195	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCL2—uterine cancer	0.000294	0.00192	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EP300—uterine cancer	0.000284	0.00186	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CA—uterine cancer	0.000275	0.00179	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—uterine cancer	0.000271	0.00177	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NRAS—uterine cancer	0.000266	0.00174	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CA—uterine cancer	0.000249	0.00163	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB2—uterine cancer	0.000245	0.0016	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL8—uterine cancer	0.000232	0.00152	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—uterine cancer	0.000231	0.00151	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—uterine cancer	0.000229	0.0015	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1B—uterine cancer	0.000227	0.00148	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT1—uterine cancer	0.000224	0.00147	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CTNNB1—uterine cancer	0.000214	0.0014	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CA—uterine cancer	0.00021	0.00137	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTEN—uterine cancer	0.000209	0.00136	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKT1—uterine cancer	0.000204	0.00133	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EP300—uterine cancer	0.000199	0.0013	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—uterine cancer	0.000195	0.00127	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—uterine cancer	0.000189	0.00123	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NRAS—uterine cancer	0.000186	0.00122	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT1—uterine cancer	0.000172	0.00112	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—uterine cancer	0.00016	0.00105	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CA—uterine cancer	0.000147	0.000962	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—uterine cancer	0.000143	0.000931	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—uterine cancer	0.000136	0.00089	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT1—uterine cancer	0.00012	0.000786	CbGpPWpGaD
